Dr. med. Dr. rer. nat. Daniel Rupp

Identification of HNRNPK as regulator of hepatitis C virus particle production.
_{Poenisch M, Blankenburg H, Metz P, Ruggieri A, Lee JY, Rupp D, Rebhan I, Diederich K, Kaderali L, Domingues F, Albrecht M, Lohmann V, Erfle H, Bartenschlager R.
PLoS Pathog. 2015 Jan8;11(1):e1004573. doi: 10.1371/journal.ppat.1004573. eCollection 2015 Jan.} 

Development of a high-throughput pyrosequencing assay for monitoring temporal evolution and resistance associated variant emergence in the Hepatitis C virus protease coding-region.
_{Rupp D, Irving WL, McClure CP, Than LM, Titman A, Ball JK, Steinmann E, Bartenschlager R, Pietschmann T, Brown RJ.
Antiviral Res. 2014 Oct;110:52-9. doi: 10.1016/j.antiviral.2014.07.009. Epub 2014 Jul 22.}

Targets for antiviral therapy of hepatitis C.
_{Rupp D, Bartenschlager R.
Semin Liver Dis. 2014 Feb;34(1):9-21. doi: 10.1055/s-0034-1371006. Epub 2014 Apr 29.}

Evidence for novel hepaciviruses in rodents.
_{Drexler JF, Corman VM, Müller MA, Lukashev AN, Gmyl A, Coutard B, Adam A, Ritz D, Leijten LM, van Riel D, Kallies R, Klose SM, Gloza-Rausch F, Binger T, Annan A, Adu-Sarkodie Y, Oppong S, Bourgarel M, Rupp D, Hoffmann B, Schlegel M, Kümmerer BM, Krüger DH, Schmidt-Chanasit J, Setién AA, Cottontail VM, Hemachudha T, Wacharapluesadee S, Osterrieder K, Bartenschlager R, Matthee S, Beer M, Kuiken T, Reusken C, Leroy EM, Ulrich RG, Drosten C.
PLoS Pathog. 2013;9(6):e1003438. doi: 10.1371/journal.ppat.1003438. Epub 2013 Jun 20.} 

Poor performance of bioinformatics programs for genotypic prediction of coreceptor usage of HIV1 group O isolates.
_{Rupp D, Geuenich S, Keppler OT.
J Acquir Immune Defic Syndr. 2010 Mar 1;53(3):412-3.}

Antagonism of CD317 restriction of human immunodeficiency virus type 1 (HIV-1) particle release and depletion of CD317 are separable activities of HIV-1 Vpu.
_{Goffinet C, Homann S, Ambiel I, Tibroni N, Rupp D, Keppler OT, Fackler OT.
J Virol. 2010 Apr;84(8):4089-94. Epub 2010 Feb 10}

HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor.
_{Goffinet C, Allespach I, Homann S, Tervo HM, Habermann A, Rupp D, Oberbremer L, Kern C, Tibroni N, Welsch S, Krijnse-Locker J, Banting G, Kräusslich HG, Fackler OT, Keppler OT.
Cell Host Microbe. 2009 Mar 19;5(3):285-97}